Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia

Sponsor
Johann Wolfgang Goethe University Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03357978
Collaborator
(none)
30
1
1
35.9
0.8

Study Details

Study Description

Brief Summary

Ataxia telangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The immunodeficiency is expressed by recurring infections. It's characterised by decreased lymphocytes data as well as lack of immunglobulin A, immunglobulin G subclasses and specific antibodies against pneumococcus. Aim of the present clinical trial is to investigate frequency-, intensity- and duration of the infections as well as changes oft immune status, dimension of liver disease and tumor risk in patients with A-T, with and without immunoglobulin G substitution therapy. Transient elastography (FibroScan) will be performed in order to measure liver stiffness as an indication of fatty liver and liver fibrosis. A bioelectrical impedance analysis (BIA) is conducted to investigate the exact body composition. Ataxia Score is determined to define neurological problems. Every subject receives a diary to compile symptoms of infection.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: bioelectrical impedance analysis
  • Diagnostic Test: blood draw
  • Diagnostic Test: transient elastography (FibroScan)
  • Diagnostic Test: ataxia score
  • Diagnostic Test: Five-Times-Sit-to-Stand Test
N/A

Detailed Description

Ataxia teleangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The immunodeficiency is expressed by recurring infections. It's characterised by decreased lymphocytes data as well as lack of immunglobulin A, immunglobulin G subclasses and specific antibodies against pneumococcus as shown in many trials. Additionally the patients suffer from a fatty liver with increased transaminases and have the risk for a cirrhosis of the liver and a hepatocellular carcinoma. It's known that the dimension of the liver disease affects susceptibility to infection. Nevertheless there are only a few studies treating this problem.

Despite the proof of the immunodeficiency polyvalent immunoglobulins (IgG) are not given regularly. Own observations show that in spite of the treatment with immunoglobulins the progression of a chronic destructive lung disease with development of bronchiectasis hardly can prohibited.

Up to now it isn't cleared if a substitution therapy with immunoglobulins reduces the susceptibility to infection. Therefore the aim oft the present clinical trial ist to explore frequency-, intensity, and duration oft the infections as well as changes oft the immune status, measure of liver disease and tumor risk in patients with A-T, with and without immunoglobulin therapy. The study includes five visits, which are performed in all A-T patients. Visit 1, 3, 5 are realized in the context of annual follow ups:

  • To evaluate weight and length of all subjects

  • To analyze the exact structure of single body compartments such as the lean mass, the water compartment or the fat compartment using bioelectrical impedance analysis

  • To define the neurological status by ataxia score

  • To get a detailed immune status, vaccination status and liver values as well as special tumor markers in blood

  • To check the lung function using spirometry

  • To measure liver stiffness using transient elastography (FibroScan)

  • To compile any symptoms of infection by diary

  • To investigate the ataxia status and physical condition by means of the Five-Times-Sit-to-Stand Test

Visit 2 and 4 are additionally conducted as study visits:
  • To get a detailed immune status in blood

  • To check the lung function using spirometry

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia With and Without Substitution of Immunoglobulin G: a Prospective Observational Study
Actual Study Start Date :
Oct 1, 2016
Anticipated Primary Completion Date :
Sep 30, 2018
Anticipated Study Completion Date :
Sep 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Other: A-T patients

A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution bioelectrical impedance Analysis blood draw transient elastography (FibroScan) ataxia score Five-Times-Sit-to-Stand Test

Diagnostic Test: bioelectrical impedance analysis
Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body

Diagnostic Test: blood draw
Blood samples are taken from sober patients

Diagnostic Test: transient elastography (FibroScan)
FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound

Diagnostic Test: ataxia score
Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb

Diagnostic Test: Five-Times-Sit-to-Stand Test
The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series

Outcome Measures

Primary Outcome Measures

  1. Infections in A-T [24 months]

    Evaluation of frequency, severity and intensity of infections in A-T patients with and without immunoglobulin G substitution

Secondary Outcome Measures

  1. Liver disease [24 months]

    Evaluation of the degree of liver disease measured by liver enzymes and structural changes by transient elastography (Fibroscan) in A-T patients

  2. Cancer risk [24 months]

    Evaluation of tumor markers in A-T patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • aim group: genetically and/or clinically diagnosed A-T

  • age 2-45 years

  • written informed consent

Exclusion Criteria:
  • age < 2 or > 45 years

  • other diseases with influence on the immune system (i.e. diabetes mellitus, malignoma, dialysis-dependent renal failure)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Children's Hospital, Allergology, Pneumology and Cystic Fibrosis, Goethe University Frankfurt Frankfurt Hessen Germany 60590

Sponsors and Collaborators

  • Johann Wolfgang Goethe University Hospital

Investigators

  • Principal Investigator: Stefan Zielen, Prof. Dr., Children's Hospital, Allergology, Pneumology and Cystic Fibrosis, Goethe-University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stefan Zielen, Prof. Dr. med. Stefan Zielen, Johann Wolfgang Goethe University Hospital
ClinicalTrials.gov Identifier:
NCT03357978
Other Study ID Numbers:
  • InfectionandLiver_AT2016
First Posted:
Nov 30, 2017
Last Update Posted:
Nov 30, 2017
Last Verified:
Nov 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Stefan Zielen, Prof. Dr. med. Stefan Zielen, Johann Wolfgang Goethe University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 30, 2017